Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03117751Phase 3Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Mar 2017
- Primary completion
- Sep 2026
- Modality
- Irreversible Covalent Inhibitors, Targeted Protein Degraders (TPDs), Antibody Conjugates
- Countries
- 2
01
Overview
A Phase 3 trial of blinatumomab, bortezomib, ruxolitinib, dasatinib, nelarabine in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LBL), sponsored by St. Jude Children's Research Hospital. Started Mar 2017; status: active, not recruiting.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LBL)
Beyond the preview
Go deeper on NCT03117751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117751.